Pipeline and Milestones - Prothena has multiple clinical programs ongoing, including one partnered Phase 3 program, two partnered Phase 2 programs, one partnered Phase 1 program, and one wholly-owned Phase 1 program[13] - Prothena is eligible to receive up to $1.23 billion in total consideration from Novo Nordisk for coramitug and the broader ATTR amyloidosis program[13, 16] - Prothena anticipates up to $105 million in clinical milestones in 2026, including completion of Phase 3 development for prasinezumab and initial data from the Phase 1 ASCENT trial for PRX012[18] Partnerships and Financials - Prothena's partnerships are expected to generate meaningful value, with up to $755 million in total milestones and royalties for prasinezumab, up to $1.23 billion for coramitug, and up to $1.55 billion across two clinical-stage programs (BMS-986446 and PRX019)[20] - Bristol Myers Squibb (BMS) owns approximately 2.2% of Prothena's outstanding shares as of March 3, 2025[21] Alzheimer's Disease Programs - PRX012, Prothena's anti-Aβ candidate, has approximately 10X greater binding potency to fibrillar Aβ vs aducanumab and approximately 20X greater binding potency against protofibrils vs lecanemab[24] - BMS-986446 (formerly PRX005), an anti-tau candidate, has the potential to reduce pathogenic tau spread in Alzheimer's disease[27] - PRX123, a dual Aβ/tau vaccine candidate, is designed for both treatment and prevention of Alzheimer's disease, and its IND has been cleared[27] Parkinson's Disease Program - Roche will initiate Phase 3 development for prasinezumab in early-stage Parkinson's disease[15, 111] - The Parkinson's disease affects >10 million people worldwide and represents an overall economic burden of $52 billion in the US[5] ATTR Amyloidosis Program - Coramitug (formerly PRX004) is in Phase 2 development for ATTR amyloidosis with cardiomyopathy (ATTR-CM)[15, 142] - An estimated 450,000 patients worldwide have wtATTR or ATTRv[8]

Shares of Prothena (PRTA) tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the development of the pipeline candidate, birtamimab.The decision to discontinue comes after the late-stage AFFIRM-AL clinical study evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.The company’s shares have lost 52.5% year to date compared with the industry’s decline of 5%.Image Source: Zacks Investment ResearchMore on PRTA’s BirtamimabBirtamimab was a w ...

Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.AL (amyloid light-chain) amyloidosis is a systemic disease where abnormal proteins, called amyloid fibrils, accumulate in various organs. It’s the most common type of systemic amyloidosis.The Phase 3 AFFIRM-AL trial enrolled 207 newly diagnosed patients. Birtamimab was given to the active arm every 28 days at a dose level of 24 mg/kg (maximum dose not to excee ...

Prothena Corporation (PRTA) reported first-quarter 2025 loss per share of $1.12, much wider than the Zacks Consensus Estimate of a loss of 92 cents.  In the year-ago quarter, the company posted a loss of $1.34 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The bottom line improved year over year due to higher revenues and lower expenses.Revenues totaled $2.8 million, which missed the Zacks Consensus Estimate of $21 million. PRTA recorded revenues of $0.1 million in the f ...

Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -21.74%. A quarter ago, it was expected that this drug developer would post a loss of $1.02 per share when it actually produced a loss of $1.08, delivering a surprise of -5.88%.Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) ______________________________________ Ireland 98-1111119 (St ...

Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2025 Financial Results and Business Highlights DUBLIN, Ireland, May 8, 2025 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2025 and provided business highlights. "We continue to meaningfully advance our wholly-owned and partnered programs across our protein d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATIO ...

Prothena Corporation (PRTA) reported fourth-quarter 2024 loss per share of $1.08, wider than the Zacks Consensus Estimate of a loss of $1.02.  In the year-ago quarter, the company posted a loss of $1.26 cents per share.The bottom line improved year over year due to higher revenues and lower expenses.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenues totaled $2.1 million, which missed the Zacks Consensus Estimate of $14 million. PRTA recorded revenues of $316,000 for the fourth q ...

Prothena Fourth Quarter and Year-End 2024 Financial Results February 20, 2025 4Q and FY24 Earnings Call Agenda | Welcome | Mark Johnson Vice President of Investor Relations | | --- | --- | | Opening Remarks | Gene Kinney, Ph.D. President and CEO | | R&D Update | Chad Swanson, Ph.D. Chief Development Officer | | Commercial Update | Brandon Smith Chief Operating Officer | | Financial Results | Tran Nguyen Chief Financial Officer and Chief Strategy Officer | | Closing Remarks | Gene Kinney, Ph.D. President and ...